Samsung Biologics announced on Feb. 13 that it has been awarded the Leadership A- grade in the climate change response category by global sustainability evaluation organization Carbon Disclosure Project (CDP). CDP, a non-profit international organization founded in the U.K. in 2000, conducts project
The pharmaceutical patent disputes between domestic biosimilar companies and original pharmaceutical firms are escalating.According to industry sources on Jan. 31, Samsung Bioepis and Celltrion are embroiled in patent disputes with original pharmaceutical companies.Alexion Pharmaceuticals, a subsidi
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Gene cell therapy approaches are gradually gaining renewed attention in response to recent CRISPR and CAR-T news. GCT received keen attention in 2H20 as a viral vector and mRNA-based coronavirus vacc
On Nov. 27, Incheon Free Economic Zone Authority (IFEZ) announced that a delegation of 11 researchers, including Professor Han Nam-sik, AI Center Director at the Milner Research Institute affiliated with the University of Cambridge, and Senior Researcher Georgia Sakkoziorga visited IFEZ. They toured
The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Yuhan, 1Q23 non-consolidated and consolidated OP likely came in at respective W14.6bn (beating consensus) and W13.3bn (missing consensus). We anticipate consolidated earnings improvement after com
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, and the International Vaccine Institute (IVI) have jointly announced Profs. Andrew Pollard and Sarah Gilbert and Drs. Rino Rappuoli and Mariagrazia Pizza as two groups of co-re
EQT Partners, a private equity fund (PEF), has finalized the acquisition of SK Shieldus, a security business affiliate of SK Group. EQT will sign a stock purchase agreement (SPA) worth three trillion won with SK Shieldus this week. It will take over about 30 percent of the 63.1 percent stake held by
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Laser301 data were recently released at the ESMO Asia Congress 2022. Against this backdrop, attention is turning to Janssen’s commercialization strategy for Lazertinib. A competing phase III clinical
EQT Partners, a private equity fund operated by Sweden’s largest conglomerate Wallenberg Group, is reportedly promoting an investment of about 2 trillion won in SK Shieldus, a Korean security company.Wallenberg Group has invested in major global companies through diverse investment arms. It has stak
The Korean Ministry of Food and Drug Safety (KMFDS) has authorized South Korea's first homegrown COVID-19 vaccine from SK bioscience.South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.SKYCovione is a self-assembled
The birth of a Korean COVID-19 vaccine is imminent. Korean public health authorities are expected to approve SK Bioscience’s SKY Covione (candidate substance GBP510) as early as this week. If the final approval is given as expected, Korea's first and only COVID-19 vaccine will be used at vaccina
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. ctDNA technology a game changerAt this year’s ASCO conference, circulating tumor DNA (ctDNA) was at the center of attention. Though various technological challenges need to be tackled first for full-
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
The National Academy of Medicine of Korea announced on May 12 that there is a causality between the Pfizer and Moderna COVID-19 vaccines and acute pericarditis.The academy conducted self-controlled case series analysis for a post-inoculation period of six weeks. “When it comes to initial inoculation
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In January, NYSE pharmaceuticals indices tumbled, with both large caps and small caps being weighed upon by adverse macro conditions. However, the coupling between Covid-19 sentiment and biotech appe
SK Group chairman Chey Tae-won met with Conni Jonsson, chairman of Swedish investment company EQT Partners AB, which is affiliated with the Wallenberg Family, on Dec. 3 and discussed ways to cooperate with each other.The Wallenberg Family is considered one of the world’s best business groups in the
The South Korean government announced on Nov. 16 that the number of South Koreans fully vaccinated against COVID-19 increased by 87,466 to 40,193,024 on Nov. 15.That day, the ratio of those fully vaccinated to the entire population reached 78.3 percent and the ratio to those aged at least 18 reached
Sweden's Wallenberg family is promoting equity investment in SK Group’s ADT Caps through EQT Partners, Sweden's largest private equity fund operator established by the Swedish business empire.ADT Caps, a subsidiary of SK Telecom, is seeking a pre-IPO worth 300 billion won. EQT Partners has t